{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T11:45:25Z","timestamp":1794570325764,"version":"4.9.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T00:00:00Z","timestamp":1776124800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"vor","delay-in-days":38,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100011958","name":"Danmarks Frie Forskningsfond","doi-asserted-by":"publisher","award":["4308-00118B9"],"award-info":[{"award-number":["4308-00118B9"]}],"id":[{"id":"10.13039\/501100011958","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Fonden","doi-asserted-by":"publisher","award":["NNF24OC0095318"],"award-info":[{"award-number":["NNF24OC0095318"]}],"id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-026-15784-y","type":"journal-article","created":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T09:34:39Z","timestamp":1776159279000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["SENIPERA Phase 0\/1 randomized window-of-opportunity clinical trial of SENIcapoc and PERAmpanel mono- and combination therapy of newly diagnosed glioblastoma: a trial protocol"],"prefix":"10.1186","volume":"26","author":[{"given":"Jens Toft","family":"Eschen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Line Louise","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Hausmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allice Nyborg Rosenkrans","family":"Lind","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Slavka","family":"Lukacova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"Weischenfeldt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrik","family":"Lassen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manfred","family":"Westphal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Winkler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulf","family":"Simonsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders Rosendal","family":"Korshoej","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,14]]},"reference":[{"issue":"1","key":"15784_CR1","doi-asserted-by":"publisher","first-page":"15017","DOI":"10.1038\/nrdp.2015.17","volume":"1","author":"M Weller","year":"2015","unstructured":"Weller M, Wick W, Aldape K, Brada M, Berger M, Pfister SM, et al. Glioma. Nat Rev Dis Primers. 2015;1(1):15017\u201315017.","journal-title":"Nat Rev Dis Primers"},{"key":"15784_CR2","doi-asserted-by":"crossref","unstructured":"Ostrom QT, Price M, Neff C, Cioffi G, Waite KA, Kruchko C, et al. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2015\u20132019. Neuro-oncology (Charlottesville, Va). 2022;24(Supplement_5):v1\u201395.","DOI":"10.1093\/neuonc\/noac202"},{"issue":"10","key":"15784_CR3","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1038\/s41556-022-00978-w","volume":"24","author":"C Pan","year":"2022","unstructured":"Pan C, Winkler F. Insights and opportunities at the crossroads of cancer and neuroscience. Nat Cell Biol. 2022;24(10):1454\u201360.","journal-title":"Nat Cell Biol"},{"issue":"10","key":"15784_CR4","doi-asserted-by":"publisher","first-page":"2485","DOI":"10.1016\/j.cell.2024.03.029","volume":"187","author":"AC Greenwald","year":"2024","unstructured":"Greenwald AC, Darnell NG, Hoefflin R, Simkin D, Mount CW, Gonzalez Castro LN, et al. Integrative spatial analysis reveals a multi-layered organization of glioblastoma. Cell. 2024;187(10):2485-2501.e26.","journal-title":"Cell"},{"issue":"8","key":"15784_CR5","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1016\/j.cell.2023.02.002","volume":"186","author":"F Winkler","year":"2023","unstructured":"Winkler F, Venkatesh HS, Amit M, Batchelor T, Demir IE, Deneen B, et al. Cancer neuroscience: state of the field, emerging directions. Cell. 2023;186(8):1689\u2013707.","journal-title":"Cell"},{"issue":"10","key":"15784_CR6","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1093\/neuonc\/nox070","volume":"19","author":"S Weil","year":"2017","unstructured":"Weil S, Osswald M, Solecki G, Grosch J, Jung E, Lemke D, et al. Tumor microtubes convey resistance to surgical lesions and chemotherapy in gliomas. Neuro-oncol. 2017;19(10):1316\u201326.","journal-title":"Neuro-oncol"},{"issue":"7580","key":"15784_CR7","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/nature16071","volume":"528","author":"M Osswald","year":"2015","unstructured":"Osswald M, Jung E, Sahm F, Solecki G, Venkataramani V, Blaes J, et al. Brain tumour cells interconnect to a functional and resistant network. Nature (London). 2015;528(7580):93\u20138.","journal-title":"Nature (London)"},{"issue":"7775","key":"15784_CR8","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1038\/s41586-019-1564-x","volume":"573","author":"V Venkataramani","year":"2019","unstructured":"Venkataramani V, Tanev DI, Strahle C, Studier-Fischer A, Fankhauser L, Kessler T, et al. Glutamatergic synaptic input to glioma cells drives brain tumour progression. Nature (London). 2019;573(7775):532\u20138.","journal-title":"Nature (London)"},{"issue":"16","key":"15784_CR9","doi-asserted-by":"publisher","first-page":"2899","DOI":"10.1016\/j.cell.2022.06.054","volume":"185","author":"V Venkataramani","year":"2022","unstructured":"Venkataramani V, Yang Y, Schubert MC, Reyhan E, Tetzlaff SK, Wi\u00dfmann N, et al. Glioblastoma hijacks neuronal mechanisms for brain invasion. Cell. 2022;185(16):2899-2917.e31.","journal-title":"Cell"},{"issue":"7942","key":"15784_CR10","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/s41586-022-05520-4","volume":"613","author":"D Hausmann","year":"2023","unstructured":"Hausmann D, Hoffmann DC, Venkataramani V, Jung E, Horschitz S, Tetzlaff SK, et al. Autonomous rhythmic activity in glioma networks drives brain tumour growth. Nature. 2023;613(7942):179\u201386.","journal-title":"Nature"},{"issue":"8","key":"15784_CR11","doi-asserted-by":"publisher","first-page":"3991","DOI":"10.1182\/blood-2007-08-110098","volume":"111","author":"KI Ataga","year":"2008","unstructured":"Ataga KI, Smith WR, De Castro LM, Swerdlow P, Saunthararajah Y, Castro O, et al. Efficacy and safety of the Gardos channel blocker, senicapoc (ICA-17043), in patients with sickle cell anemia. Blood. 2008;111(8):3991\u20137.","journal-title":"Blood"},{"key":"15784_CR12","doi-asserted-by":"publisher","unstructured":"Granfeldt A, Andersen LW, Vallentin MF, Hilberg O, Hasselstr\u00f8m JB, S\u00f8rensen LK, et al. Senicapoc treatment in COVID\u201019 patients with severe respiratory insufficiency\u2014A randomized, open\u2010label, phase II trial. Acta Anaesthesiologica Scandinavica. 2022;66(7):838-46. https:\/\/doi.org\/10.1111\/aas.14072.","DOI":"10.1111\/aas.14072"},{"issue":"6","key":"15784_CR13","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1002\/glia.22655","volume":"62","author":"KL Turner","year":"2014","unstructured":"Turner KL, Honasoge A, Robert SM, McFerrin MM, Sontheimer H. A pro-invasive role for the Ca2+-activated K+ channel KCa3.1 in malignant glioma. Glia. 2014;62(6):971\u201381.","journal-title":"Glia"},{"issue":"4","key":"15784_CR14","doi-asserted-by":"publisher","first-page":"428","DOI":"10.21873\/cdp.10235","volume":"3","author":"S Lehrer","year":"2023","unstructured":"Lehrer S, Rheinstein PH. Increased KCNN4 expression is correlated with poor survival in lower grade glioma. Cancer Diagn Progn. 2023;3(4):428\u201332.","journal-title":"Cancer Diagn Progn"},{"issue":"15","key":"15784_CR15","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1038\/onc.2009.25","volume":"28","author":"H Lallet-Daher","year":"2009","unstructured":"Lallet-Daher H, Roudbaraki M, Bavencoffe A, Mariot P, Gacki\u00e8re F, Bidaux G, et al. Intermediate-conductance Ca2+-activated K+ channels (IKCa1) regulate human prostate cancer cell proliferation through a close control of calcium entry. Oncogene. 2009;28(15):1792\u2013806.","journal-title":"Oncogene"},{"issue":"9","key":"15784_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11091285","volume":"11","author":"CJ Mohr","year":"2019","unstructured":"Mohr CJ, Gross D, Sezgin EC, Steudel FA, Ruth P, Huber SM, et al. KCa3.1 channels confer radioresistance to breast cancer cells. Cancers (Basel). 2019;11(9):1285.","journal-title":"Cancers (Basel)"},{"issue":"11\u201312","key":"15784_CR17","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1007\/s00424-016-1891-9","volume":"468","author":"B Bonito","year":"2016","unstructured":"Bonito B, Sauter DRP, Schwab A, Djamgoz MBA, Novak I. KCa3.1 (IK) modulates pancreatic cancer cell migration, invasion and proliferation: anomalous effects on TRAM-34. Pflugers Arch. 2016;468(11\u201312):1865\u201375.","journal-title":"Pflugers Arch"},{"issue":"1","key":"15784_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11010109","volume":"11","author":"CJ Mohr","year":"2019","unstructured":"Mohr CJ, Steudel FA, Gross D, Ruth P, Lo WY, Hoppe R, et al. Cancer-associated intermediate conductance Ca2+-activated K+ channel KCa3.1. Cancers (Basel). 2019;11(1):109.","journal-title":"Cancers (Basel)"},{"issue":"12","key":"15784_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-022-05463-8","volume":"13","author":"M Bachmann","year":"2022","unstructured":"Bachmann M, Rossa A, Varanita T, Fioretti B, Biasutto L, Milenkovic S, et al. Pharmacological targeting of the mitochondrial calcium-dependent potassium channel KCa3.1 triggers cell death and reduces tumor growth and metastasis in vivo. Cell Death Dis. 2022;13(12):1055\u201319.","journal-title":"Cell Death Dis"},{"issue":"2","key":"15784_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2017.6","volume":"8","author":"D Bauer","year":"2017","unstructured":"Bauer D, Werth F, Nguyen HA, Kiecker F, Eberle J. Critical role of reactive oxygen species (ROS) for synergistic enhancement of apoptosis by vemurafenib and the potassium channel inhibitor TRAM-34 in melanoma cells. Cell Death Dis. 2017;8(2):e2594\u2013e2594.","journal-title":"Cell Death Dis"},{"key":"15784_CR21","doi-asserted-by":"crossref","unstructured":"Grimaldi A, D\u2019Alessandro G, Golia MT, Gr\u00f6ssinger EM, Di Angelantonio S, Ragozzino D, et al. KCa3.1 inhibition switches the phenotype of glioma-infiltrating microglia\/macrophages. Cell Death Dis. 2016;7(4):e2174\u2013e2174.","DOI":"10.1038\/cddis.2016.73"},{"key":"15784_CR22","doi-asserted-by":"crossref","unstructured":"D\u2019Alessandro G, Grimaldi A, Chece G, Porzia A, Esposito V, Santoro A, et al. KCa3.1 channel inhibition sensitizes malignant gliomas to temozolomide treatment. Oncotarget. 2016;7(21):30781\u201396.","DOI":"10.18632\/oncotarget.8761"},{"key":"15784_CR23","doi-asserted-by":"publisher","unstructured":"Heuer S, Burghaus I, Gose M, et al. PerSurge (NOA-30) phase II trial of perampanel treatment around surgery in patients with progressive glioblastoma. BMC Cancer. 2024;24:135. https:\/\/doi.org\/10.1186\/s12885-024-11846-1.","DOI":"10.1186\/s12885-024-11846-1"},{"issue":"11","key":"15784_CR24","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1592\/phco.26.11.1557","volume":"26","author":"KI Ataga","year":"2006","unstructured":"Ataga KI, Orringer EP, Styles L, Vichinsky EP, Swerdlow P, Davis GA, et al. Dose-escalation study of ICA-17043 in patients with sickle cell disease. Pharmacotherapy. 2006;26(11):1557\u201364.","journal-title":"Pharmacotherapy"},{"key":"15784_CR25","unstructured":"Dansk Neuro-Onkologisk Gruppe. Gliomer hos voksne \u2502Kliniske retningslinjer . 2024. Available from: https:\/\/dnog.dk\/onewebmedia\/files\/Retningslinier%20PDF\/DNOG_Gliomer_v4.0_AdmGodk_161224.pdf.\u00a0Cited 22 Mar 2025."},{"issue":"10","key":"15784_CR26","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987\u201396.","journal-title":"N Engl J Med"},{"key":"15784_CR27","doi-asserted-by":"crossref","unstructured":"Wen PY, van den Bent M, Youssef G, Cloughesy TF, Ellingson BM, Weller M, et al. RANO 2.0: Update to the Response Assessment in Neuro-Oncology Criteria for High- and Low-Grade Gliomas in Adults. Journal of clinical oncology. 2023;41(33):5189\u201399.","DOI":"10.1200\/JCO.2023.41.16_suppl.2017"},{"key":"15784_CR28","doi-asserted-by":"publisher","unstructured":"Hai L, Hoffmann DC, Wagener RJ, Azorin DD, Hausmann D, Xie R, et al. A clinically applicable connectivity signature for glioblastoma includes the tumor network driver CHI3L1. Nature Communications. 2024;15(1):968. https:\/\/doi.org\/10.1038\/s41467-024-45067-810.1038\/s41467-024-45067-8.","DOI":"10.1038\/s41467-024-45067-810.1038\/s41467-024-45067-8"},{"key":"15784_CR29","unstructured":"Drexler R, Khatri R, Sauvigny T, Mohme M, Maire CL, Ryba A, et al. A prognostic neural epigenetic signature in high-grade glioma. Nat Med . 2024 May 17; Available from: https:\/\/www.nature.com\/articles\/s41591-024-02969-w."},{"key":"15784_CR30","unstructured":"U.S. Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE) Common Terminology Criteria for Adverse Events (CTCAE) v5.0. 2017. Available from: https:\/\/www.meddra.org\/."},{"issue":"1","key":"15784_CR31","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1215\/15228517-2006-025","volume":"9","author":"KV Ballman","year":"2007","unstructured":"Ballman KV, Buckner JC, Brown PD, Giannini C, Flynn PJ, LaPlant BR, et al. The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme. Neuro Oncol. 2007;9(1):29\u201338.","journal-title":"Neuro Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-15784-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15784-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15784-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T01:30:15Z","timestamp":1779413415000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-15784-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,14]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["15784"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-15784-y","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,14]]},"assertion":[{"value":"25 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study has been approved by the Danish Medicines Agency (\n                      L\u00e6gemiddelstyrelsen\n                      ) and by the National Committee on Health Research Ethics (\n                      De Videnskabsetiske Medicinske Komit\u00e9er\n                      ) (EU-CT: 2025\u2013522605-37\u201300, authorized 14 October 2025). The trial will be conducted in accordance with the principles of the Declaration of Helsinki, the ICH-GCP guidelines, and all applicable Danish and European legislation. Written informed consent will be obtained from all participants before any trial-related activities by a qualified study team member. It may be withdrawn at any time without consequences for subsequent clinical care in accordance with Danish legislation. The Danish Patient Compensation Association will cover all patient injuries.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"667"}}